Increased oxidative stress as a risk factor in chronic idiopathic axonal polyneuropathy by Zis, P. et al.
This is a repository copy of Increased oxidative stress as a risk factor in chronic idiopathic 
axonal polyneuropathy.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/152717/
Version: Published Version
Article:
Zis, P., McHugh, P.C., Manca, M. et al. (3 more authors) (2018) Increased oxidative stress 
as a risk factor in chronic idiopathic axonal polyneuropathy. Journal of Molecular 
Neuroscience, 66 (4). pp. 547-551. ISSN 0895-8696 
https://doi.org/10.1007/s12031-018-1200-5
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Increased Oxidative Stress as a Risk Factor in Chronic Idiopathic Axonal
Polyneuropathy
Panagiotis Zis1 & Patrick C. McHugh2 & Maurizio Manca2 & Ptolemaios Georgios Sarrigiannis1 &
Dasappaiah Ganesh Rao1 & Marios Hadjivassiliou1
Received: 31 July 2018 /Accepted: 17 October 2018 /Published online: 22 October 2018
# The Author(s) 2018
Abstract
Chronic idiopathic axonal polyneuropathy (CIAP) is a disorder with insidious onset and slow progression, where no etiology is
identified despite appropriate investigations. We aimed to investigate the role of oxidative stress as a risk factor for the patho-
genesis of CIAP. Sera of patients with CIAP were tested for protein carbonyl (PC) and 8-hydroxydeoxyguanosine (8H). As a
control group, we recruited patients with gluten neuropathy. Twenty-one patients with CIAP and 21 controls were recruited. The
two groups did not differ significantly regarding demographics or clinical characteristics (i.e., neuropathy type or disease
severity). After adjusting for gender, having CIAP was positively correlated with both the 8H titer (standardized beta coefficient
0.349, p = 0.013) and the PC titer (standardized beta coefficient 0.469, p = 0.001). Oxidative stress appears to be increased in
CIAP and might have a role in the pathogenesis of the disease.
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Introduction
Chronic idiopathic axonal polyneuropathy (CIAP) is a term
describing neuropathies where neurophysiology reveals axo-
nal damage, their onset is insidious and shows slow or no
progression of the disease over at least 6 months and no etiol-
ogy is identified despite appropriate investigations (Zis et al.
2016). The majority of CIAP patients have a sensorimotor
axonal peripheral neuropathy. The second commonest idio-
pathic large fiber polyneuropathy where axons degenerate is
the sensory ganglionopathy (SG) (Zis et al. 2016).
Robust epidemiological data on polyneuropathies of any
cause are lacking. Very few studies have accurately assessed
the prevalence of polyneuropathy in the general population.
The current estimates are between 5.5% (Hanewinckel et al.
2016) and 8.0% (Italian General Practitioner Study Group
(IGPSG) 1995) in people more than 55 years. CIAP is reported
to account for up to a third of polyneuropathies of any cause
(Smith and Singleton 2004); however, the percentage of idio-
pathic polyneuropathies has declined with time (Singer et al.
2012) and the explanation for this is threefold. Firstly, with time
and adequate follow-up, more causes of polyneuropathy—he-
reditary or acquired—have been recognized; secondly, more
diagnostic tests have become available; thirdly, investigations
about possible causes of polyneuropathymay have been incom-
plete (Zis et al. 2016).
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Oxidative stress is increased in neurodegenerative diseases
such as Alzheimer’s disease (Zis et al. 2012, 2014, 2017a; Zis
and Strydom 2018) and it has been suggested that it plays a
role in the pathogenesis of polyneuropathy in diabetes
(Sifuentes-Franco et al. 2017), by causing damage to the lipids
present in the myelinated structures of the nerves, resulting in
the loss of axons and interruption of the microvasculature in
the peripheral nervous system (Kasznicki et al. 2012).
The aim of this case-controlled study was to investigate
the role of oxidative stress as a risk factor for the patho-
genesis of CIAP.
Methods
Procedure and Participants
This was a cross-sectional case-controlled study.
Patients with CIAP were recruited from a dedicated neuro-
muscular clinic based at the Royal Hallamshire Hospital
(Sheffield, UK). To be enrolled, the patients had to meet the
following inclusion criteria: (1) clinical diagnosis of peripheral
neuropathy (PN), confirmed on nerve conduction studies (NCS),
(2) absence of other risk factors for developing PN (i.e., diabetes,
vitamin deficiencies, exposure to neurotoxic agents), (3) normal
results on an extensive diagnostic work-up (Zis et al. 2016), and
(4) able to provide a written informed consent.
Individuals suffering from gluten neuropathy (GN) partici-
pated in the study forming a control group of patients with PN
of a known etiology. To be enrolled, the controls had tomeet the
following inclusion criteria: (1) diagnosis of PN, as confirmed
on nerve conduction studies, (2) serological evidence of gluten
sensitivity (positive for antigliadin IgG and/or IgAwith or with-
out positivity for endomysial and transgultaminase antibodies)
at diagnosis prior to commencing gluten-free diet, (3) absence
of other risk factors for developing PN (i.e., diabetes, vitamin
deficiencies, exposure to neurotoxic agents), and (4) able to
provide a written informed consent.
The study protocol was approved by the local ethics
committee.
Measures
Demographic characteristics included age and gender. All pa-
tients and controls went through extensive investigations for
possible causes of PN (Zis et al. 2016). Patients with a family
history of neuropathy were excluded.
The type of neuropathy (sensorimotor length-dependent
PN, sensory ganglionopathy (Zis et al. 2017b), mononeuritis
multiplex) for all patients was determined based on nerve
conduction studies, which were performed by the same clini-
cian on the day of the recruitment.
The severity of neuropathy was assessed by the overall
limitations neuropathy scale (ONLS), which is a validated
scale that measures limitations in the everyday activities of
the upper and lower limbs (Graham and Hughes 2006).
Oxidative stress markers in patients’ sera were analyzed
through ELISA assay kits (Bioassay Technology Laboratory)
according to manufacturers’ instruction. For the PC ELISA kit,
the sensitivity was 1.07 ng/ml while for the 8H ELISA kit was
0.25 ng/ml.
In brief, 40 μl of sample was added to each well and mixed
with 10 μl of antibody. After addition of 50 μl of streptavidin-
HPR, the samples were incubated for 60 min at 37 °C follow-
ed by five washes with supplied buffer. After addition of 50 μl
of substrate solution A and 50 μl of substrate solution B, the
samples were further incubated at 37 °C for 10 min in the
dark. Finally after the addition of 50 μl of stop solution, the
samples’ optical density was assessed with an Infinite F50
(Tecan) plate reader at 450 nm. Each reading was plotted
against the standard curve generated in the assay to retrieve
the sample concentration.
Statistical Analyses
A database was developed using the Statistical Package for
Social Science (version 23.0 for Mac; SPSS). Frequencies and
descriptive statistics were examined for each variable.
Comparisons between CIAP and GN patients were made
using Mann-Whitney’s U test for non-normally distributed
and chi square or Fischer’s exact test for categorical data.
Correlations between continuous variables were examined
using Spearman’s tests. Multivariate regression analyses were
performed when statistically significant differences or trends
for statistically significant differences between groups were
found in multiple variables.
The level of statistical significance was set at the 0.05 level.
Results
Our study population consisted of 21 patients with CIAP
and 21 patients with GN. The two groups did not differ
significantly regarding age, gender, neuropathy type, and
disease severity.
Neither PC nor 8H correlated significantly with age, neu-
ropathy type, or disease severity in either group. Male pa-
tients, however, showed increased PC (168.6 ± 66.4 ng/ml
versus 113.0 ± 21.3 ng/ml, p = 0.005) and increased 8H
(29.2 ± 10.1 ng/ml versus 19.6 ± 3.3 ng/ml, p = 0.002) com-
pared to females.
The univariate analysis showed that patients with CIAP
had a significantly higher PC titer compared to GN patients
(184.7 ± 73.9 ng/ml versus 126.0 ± 30.8 ng/ml, p = 0.012) in-
dicating increased oxidative stress (Table 1).
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After adjusting for gender, having CIAP was positively
correlated with both the 8H titer (standardized beta coefficient
0.349, p = 0.013) and the PC titer (standardized beta coeffi-
cient 0.469, p = 0.001).
Discussion
This case-controlled study demonstrates that patients with
neuropathy of unknown etiology (CIAP) have significantly
increased oxidative stress compared to a well-defined control
group of patients with neuropathy of a known etiology (gluten
neuropathy). This suggests that increased oxidative stress
might be a risk factor for developing CIAP.
A strength of our study design is that we compared two
groups of patients that did not differ regarding demographic
and clinical characteristics. Moreover, our patients are under
regular follow-up in our department since their diagnosis. By
repeatedly performing extensive tests, as has been suggested
for an accurate diagnosis of neuropathy of unknown etiology
(Zis et al. 2016), we were able to accurately exclude patients
with other comorbidities that increase the risk for the devel-
opment of peripheral neuropathy (i.e., diabetes, excessive al-
cohol drinking, and B12 deficiency).
The role of oxidative stress has been studied in diabetic
neuropathy and data from human and animal studies suggest
that glucose-derived oxidative stress plays an important role in
impaired neurotrophic support (Greene et al. 1999). Both
chronic and acute hyperglycemia cause oxidative stress in the
peripheral nervous system that can promote the development of
diabetic neuropathy (Vincent et al. 2004). Similarly, studies on
hepatitis C virus-associated mixed cryoglobulinemia vasculitis
neuropathy (Saadoun et al. 2007), alcohol-related neuropathy
(Kaur et al. 2017) oxaliplatin-induced sensory neuropathy
(Joseph et al. 2008), docetaxel-induced neuropathy (Mir et al.
2009), and placlitaxel-induced neuropathy (Duggett et al. 2016)
show that increased oxidative stress plays a key role and in fact
might also explain the increased prevalence of pain in such
neuropathies (Brozou et al. 2018; Artemiadis and Zis 2018).
To our knowledge, ours is the first study to investigate the role
of oxidative stress in CIAP.
In our study, we chose to analyze 8H and PC in patients’ sera.
Protein carbonyls are among the most used markers for
protein oxidation and more in general for oxidative stress
(Dalle-Donne et al. 2003). In addition they are extremely sta-
ble in plasma in the proper storing conditions (Stadtman and
Levine 2003).
In a recent study, Almogbel and Rasheed showed that pa-
tients with diabetic neuropathy show higher levels of protein
carbonyl compared to controls (Almogbel and Rasheed 2017).
Similarly, 8-hydroxydeoxyguanosine is regarded as a
marker for reactive oxidative species (ROS)–induced DNA-
modification which can be found in both serum and urine
(Lunec et al. 2002). Also, it has been shown that nerves in
rat subjects with diabetes contain an increased number of
macrophages and 8-hydroxydeoxyguanosine-positive cells
in the endoneurium (Mizukami et al. 2011). Interestingly, the
latter are significantly suppressed by methylcobalamin treat-
ment (Mizukami et al. 2011).
The fact that oxidative stress is increased in patients with
neuropathy and might play an even more important role in
those patients where no cause for their neuropathy is identified
(CIAP) broadens future research fields. Interventional studies
of agents reducing oxidative stress are needed to show wheth-
er such interventions lower the progression rate of neuropathy.
Already such interventions have been tried in both animal
Table 1 Demographic and
clinical characteristics of our
study population
CIAP
(n = 21)
GN
(n = 21)
p value
Demographics
Age, in years (SD) 71.4 (7.0) 68.2 (8.6) 0.290
Male gender (%) 16 (76.2) 16 (76.2) 1.000
Clinical characteristics
Type of neuropathy 0.697
Sensorimotor axonal PN (%) 18 (85.7) 16 (76.2)
Sensory ganglionopathy (%) 3 (14.3) 5 (23.8)
Neuropathy severity
ONLS arm score (SD) 1.1 (1.0) 1.1 (0.7) 0.989
ONLS Leg score (SD) 2.0 (1.0) 1.7 (1.3) 0.443
Total ONLS score (SD) 3.1 (1.8) 2.8 (1.6) 0.530
8-Hydroxy-desoxyguanosine (8H) titer (ng/ml) 30.4 (12.1) 23.5(5.3) 0.170
Protein carbonyl (PC) titer (ng/ml) 184.7 (73.9) 126.0 (30.8) 0.012
CIAP, chronic idiopathic axonal polyneuropathy; GN, gluten neuropathy; SD, standard deviation; ONLS, overall
neuropathy limitations scale
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models with molecules such as carvedilol (Areti et al. 2017)
and resveratrol (Kumar et al. 2007) and human studies with
compounds such as calmangafodipir (Glimelius et al. 2018).
Our results should be interpreted with some caution, given
the limitations of our design. This is a cross-sectional study
based on patients attending a specialized clinic, and the results
may not be generalizable to other settings. Our sample size
was small. Although this study was controlled, a larger future
study should either include a healthy control group or a group
of patients with genetic neuropathy to confirm our findings. A
comparison with diabetic neuropathy patients, a group where
oxidative stress also plays a role, will also be interesting.
Furthermore, our cohort included patients with large fiber ax-
onal peripheral neuropathies only. Pure small fiber neuropathy
is another area that merits further consideration.
In conclusion, oxidative stress is increased in patients with
CIAP. Oxidative stress markers such as PC or 8H have a
potential as biomarkers in such patients. Lowering oxidative
stress might be a treatment option for patients with neuropathy
and, therefore, prospective interventional multicenter longitu-
dinal studies are needed.
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